2023 World Conference on Lung Cancer (Posters)-EP13.07. Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy

EP13.07. Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy - PDF(Slides)

Back to course

Pdf Summary

This document presents the results of a study on treatment patterns and outcomes in small cell lung cancer (SCLC) patients in the United States. SCLC is an aggressive form of lung cancer that accounts for about 10 to 15% of all lung cancers. While recent advancements in front-line therapy have improved survival, most patients eventually experience relapse and there are limited treatment options beyond the second-line setting. <br /><br />The study aimed to understand the real-world treatment patterns and outcomes of SCLC patients in the third-line and beyond, particularly after the introduction of front-line therapy. The authors conducted a retrospective study using electronic health records-derived data from the Flatiron Health research database. They included adult patients with histologically confirmed SCLC who had progressed after front-line platinum-based therapy and received at least two additional lines of therapy.<br /><br />The results showed that SCLC patients in the third-line setting receive various therapies with no clear standard of care. Patients in the third-line setting had poor outcomes, both in the overall study population and in a subset of patients who received front-line platinum-based therapy with anti-PD-L1 inhibitors. The median real-world overall survival in the third-line setting was around 4.5 to 6 months, and there were no significant differences in outcomes between the overall cohorts and the subsets treated with front-line therapy.<br /><br />The study highlights the need for new therapeutic options for SCLC patients in the third-line setting. However, there were some limitations to the study, such as the inclusion of primarily US community oncology patients, which may limit the generalizability of the results. The authors also noted the potential for under-capture of mortality and progression events, which could lead to overestimation of overall survival and progression-free survival.<br /><br />Overall, this study provides important insights into the treatment patterns and outcomes of SCLC patients in later lines of therapy and emphasizes the need for new therapeutic options in this patient population.

Asset Subtitle

Hossein Borghaei

Meta Tag

Speaker Hossein Borghaei

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

small cell lung cancer

treatment patterns

outcomes

United States

front-line therapy

relapse

limited treatment options

third-line setting

real-world overall survival

therapeutic options